E Fund Management Co., Ltd. Protagonist Therapeutics, Inc Transaction History

E Fund Management Co., Ltd.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$21.79 - $32.15 $51,141 - $75,456	2,347 Added 26.2%	11,304 $327,000
Q4 2023 Feb 06, 2024	SELL	$14.05 - $23.44 $126,927 - $211,756	-9,034 Reduced 50.21%	8,957 $205,000
Q3 2023 Nov 13, 2023	BUY	$16.68 - $23.66 $43,985 - $62,391	2,637 Added 17.17%	17,991 $300,000
Q2 2023 Aug 11, 2023	BUY	$18.02 - $29.36 $119,670 - $194,979	6,641 Added 76.22%	15,354 $424,000
Q1 2023 May 11, 2023	SELL	$10.78 - $25.38 $72,969 - $171,797	-6,769 Reduced 43.72%	8,713 $200,000
Q4 2022 Feb 14, 2023	SELL	$7.36 - $11.17 $61,573 - $93,448	-8,366 Reduced 35.08%	15,482 $169,000
Q3 2022 Nov 14, 2022	SELL	$7.86 - $11.71 $95,774 - $142,686	-12,185 Reduced 33.82%	23,848 $201,000
Q2 2022 Aug 15, 2022	BUY	$7.06 - $25.52 $180,686 - $653,133	25,593 Added 245.14%	36,033 $285,000
Q1 2022 May 12, 2022	BUY	$23.34 - $36.08 $169,868 - $262,590	7,278 Added 230.17%	10,440 $247,000
Q1 2021 May 12, 2021	BUY	$19.02 - $31.15 $60,141 - $98,496	3,162 New	3,162 $81,000

212

59.1M

19K

107K

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $2.25B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on E Fund Management Co., Ltd. with notifications on news.